A New Era for Sun Protection: FDA Approves Advanced UV Filter in US

SILVER SPRING, MD – June 09, 2026 – The U.S. Food and Drug Administration (FDA) today announced a landmark decision, adding bemotrizinol to its list of approved over-the-counter (OTC) sunscreen active ingredients. The move breaks a more than two-decade-long stagnation in sunscreen innovation in the United States, marking the first time a new active ingredient has been added to the OTC monograph since the late 1990s.

The approval is being hailed as a monumental victory for public health, offering American consumers access to a modern, highly effective UV filter that has been a staple in European and Asian sunscreens for years. Bemotrizinol provides robust, broad-spectrum protection against both UVA and UVB rays, a critical factor in preventing skin cancer and premature aging.

“As promised in the Trump Administration’s MAHA Strategy Report, HHS is advancing innovation by bringing a new sunscreen ingredient to the U.S. market for the first time in 20 years,” said HHS Secretary Robert F. Kennedy, Jr. “Bemotrizinol has been used safely in Europe for decades, and FDA’s action will increase competition and consumer confidence in sunscreen products.”

The Science of Superior Protection

For years, dermatologists and consumer advocates have pointed to a significant “UVA protection gap” in the American sunscreen market. While existing ingredients offered good protection against UVB rays (the primary cause of sunburn), protection against UVA rays (which penetrate deeper and contribute to aging and cancer) was often less stable and robust. Bemotrizinol, known commercially by trade names like Tinosorb S and Parsol Shield, directly addresses this deficiency.

Scientifically, bemotrizinol is a game-changer for several reasons. First, it is highly photostable, meaning it doesn’t degrade quickly when exposed to sunlight. This is a crucial advantage over older chemical filters like avobenzone, which can lose effectiveness after sun exposure, requiring more frequent reapplication. Bemotrizinol not only maintains its own integrity but can also help stabilize other UV filters in a formulation, boosting a product's overall durability.

Second, its safety profile is exceptionally strong. The FDA designated bemotrizinol as Generally Recognized as Safe and Effective (GRASE) for use by adults and children over six months old. A key reason for this is its large molecular size, which results in very low absorption through the skin into the bloodstream. This stands in stark contrast to concerns raised about older filters like oxybenzone, which have been found to have higher systemic absorption rates. The FDA’s rigorous review, which included long-term animal and reproductive studies, found no evidence of harmful effects.

Finally, bemotrizinol enables the creation of more cosmetically elegant sunscreens. Unlike mineral filters such as zinc oxide and titanium dioxide, it can be formulated into clear, lightweight lotions that don't leave a tell-tale white cast, a significant barrier to use for many consumers, especially those with deeper skin tones.

Breaking a Two-Decade Regulatory Logjam

The approval of bemotrizinol is not just a scientific milestone but also a regulatory one. It serves as the first major success story of a modernized review process established by the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020. For over 20 years, the previous pathway for approving new OTC drug ingredients was notoriously slow and burdensome, creating a logjam that left the U.S. market far behind global standards.

Under the new administrative order process, the FDA was able to finalize the approval just seven months after issuing a proposed order in December 2025. This newfound efficiency signals a potential end to the regulatory paralysis that has frustrated manufacturers and public health experts alike.

“This is exactly the kind of progress we can achieve when we modernize our processes and apply sound science to regulatory decisions,” said Mike Davis, M.D., Ph.D., Acting Director of the FDA’s Center for Drug Evaluation and Research (CDER). “The FDA is committed to ensuring the American consumer has access to the most effective and safe therapies, including over-the-counter products like sunscreens.”

The action was driven by a request from DSM Nutritional Products LLC (now part of DSM-Firmenich), which sought approval for bemotrizinol at concentrations up to 6 percent. The agency's swift and positive response aligns with priorities outlined in the Make America Healthy Again (MAHA) Strategy Report to promote innovation in the sunscreen market.

Market Impact and the Future of Sun Care

The introduction of bemotrizinol is poised to reshape the American sun care landscape. For consumers, it means the imminent arrival of a new generation of sunscreen products that offer superior, longer-lasting protection in aesthetically pleasing formulas. Advocacy organizations like the Environmental Working Group (EWG), which has long campaigned for access to modern filters, celebrated the decision as a “great day for American consumers.”

For the industry, it injects a much-needed dose of innovation and competition. As part of the approval, DSM-Firmenich will receive an 18-month period of marketing exclusivity before other companies can utilize the ingredient. Following this period, the broader market is expected to rapidly adopt bemotrizinol into new and existing product lines, raising the bar for sun protection across the board.

“The FDA’s rigorous standards ensure consumers can be confident in the sunscreens and other nonprescription drugs they use,” said Karen Murry, M.D., Director of the Office of Nonprescription Drugs in CDER. “Now, through the best available science and updated regulatory framework, we can work with companies to get innovative products to market in a more efficient manner than ever before.”

While this approval is a significant step forward, the U.S. still has ground to cover. The European Union has approved approximately 30 different UV filters, nearly double the number now available in the U.S. However, the successful and efficient approval of bemotrizinol sets a powerful precedent, offering hope that other advanced ingredients waiting in the wings may soon follow, finally giving Americans access to the world’s best defenses against the sun.